SCHEMBL30596010

SCHEMBL30596010

CCN1CCc2cc(C(=O)Nc3cccc(Br)c3Cl)ncc2C1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAP3K5 Q99683 6/20 0.47
▸ KMT2A Q03164 3/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ PDCD1 Q15116 7/20 0.40
▸ CD274 Q9NZQ7 7/20 0.40
▸ ABCB1 P08183 1/20 0.40
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MAPK8 P45983 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PRMT5 O14744 1/20 0.39
▸ WDR77 Q9BQA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24127440 1.00 MAP3K5 (0.47) MAP3K5KMT2ATP53MAPTPDCD1
SCHEMBL24127327 0.90 MAP3K5 (0.40) MAP3K5PDCD1CD274ABCB1ABCG2
SCHEMBL30595971 0.90 MAP3K5 (0.40) MAP3K5PDCD1CD274ABCB1ABCG2
SCHEMBL30595972 0.89 PDCD1 (0.51) MAP3K5PDCD1CD274ABCB1ABCG2
SCHEMBL24127341 0.89 PDCD1 (0.51) MAP3K5PDCD1CD274ABCB1ABCG2
SCHEMBL24127439 0.89 PDCD1 (0.47) MAP3K5PDCD1CD274PRMT5WDR77
SCHEMBL30389787 0.89 PDCD1 (0.47) MAP3K5PDCD1CD274PRMT5WDR77
SCHEMBL25312939 0.89 PDCD1 (0.47) MAP3K5PDCD1CD274PRMT5WDR77
SCHEMBL24127333 0.88 PRMT5 (0.42) MAP3K5KMT2APDCD1CD274ABCB1
SCHEMBL30595962 0.88 PRMT5 (0.42) MAP3K5KMT2APDCD1CD274ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552811-B2 Immunosuppressant, and preparation method therefor and use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2026-02-17 — — US disclosed
US-20230234970-A1 IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552811-B2 Immunosuppressant, and preparation method therefor and use thereof CD274, PDCD1, PDCD1LG2 MAP3K5 1802/4885KMT2A 2623/4885TP53 533/4885
US-20230234970-A1 IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF CD274, PDCD1, PDCD1LG2 MAP3K5 341/4885KMT2A 3025/4885TP53 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback